The Technical Analyst
Kindred Biosciences, Inc. [KIN]
Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Kindred Biosciences, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.11% $9.25
America/New_York / 31 des 1970 @ 19:00
| RATING 2021-08-30 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/20 | 2/20 | 3/20 | 4/20 | 1/21 | 2/21 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -9.09 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.19x |
| Company: PE -9.09 | industry: PE 47.78 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 9.17 - 9.33 ( +/- 0.89%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2021-08-27 | Park West Asset Management Llc | Sell | 6 000 002 | Common Stock, par value $0.0001 per share |
| 2021-08-27 | Wee Wendy | Sell | 78 613 | Common Stock |
| 2021-08-27 | Wee Wendy | Sell | 32 500 | Stock Option (right to buy) |
| 2021-08-27 | Wee Wendy | Sell | 10 000 | Stock Option (right to buy) |
| 2021-08-27 | Wee Wendy | Sell | 75 000 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 0.00 |
| Last 100 transactions |
| Buy: 510 888 | Sell: 9 693 361 |
Forecast:
01:40 - $10.43
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $9.25 (0.11% ) |
| Volume | 0.178 mill |
| Avg. Vol. | 1.506 mill |
| % of Avg. Vol | 11.86 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For KIN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
KIN
Kindred Biosciences, Inc., a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic classes and intellectual property portfolio. Its programs under development include interleukin-31 and interleukin-4R for canine atopic dermatitis; KIND-030 for parvovirus in dogs; KIND-510a for the control of non-regenerative anemia in cats; anti-TNF antibody for inflammatory bowel disease in dogs; and other biologics candidates. The company was founded in 2012 and is headquartered in Burlingame, California.
Latest Press Releases
2021-07-21 14:24:00 - Press Release
Shareholder Alert: Weisslaw Llp Reminds Cva, Swn, Rive, And Kin Shareholders About Its Ongoing Investigations
New york, july 21, 2021 /prnewswire/ -- if you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: joshua rubin, esq. weisslaw llp1500 broadway, 16th floor new york, ny 10036 (212) 682-3025 (888) 593-4771 stockinfo@weisslawllp.com covanta holding corporation (nyse: cva) weisslaw llp is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of covanta holding corporation (nyse: cva) in connection with the proposed acquisition of the company by eqt infrastructure.
2021-06-22 14:59:00 - Press Release
Moore Kuehn Encourages Kin, Svok, Rocr, And Dcrc Investors To Contact Law Firm
New york, june 22, 2021 /prnewswire/ -- moore kuehn, pllc, a law firm focusing in securities litigation located on wall street in downtown new york city, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. moore kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies: kindred biosciences, inc. (nasdaq: kin) kindred bioscience has agreed to merge with elanco health.
2021-06-21 13:24:00 - Press Release
Kindred Biosciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Kindred Biosciences, Inc. - Kin
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of kindred biosciences, inc. (nasdaqgs: kin) to elanco animal health incorporated (nyse: elan). under the terms of the proposed transaction, shareholders of kindred will receive only $9.25 for each share of kindred that they own. ksf is seeking to determine whether this consideration and the process that led to i
2021-06-16 19:30:00 - Press Release
Shareholder Alert: Monteverde & Associates Pc Announces An Investigation Of Kindred Biosciences, Inc. - Kin
New york, june 16, 2021 /prnewswire/ -- juan monteverde , founder and managing partner at monteverde & associates pc, a national securities firm rated top 50 in the 2018-2020 iss securities class action services report and headquartered at the empire state building in new york city, is investigating kindred biosciences, inc. ("kin" or the "company") (kin) relating to its proposed acquisition by elanco animal health, inc. kin shareholders will receive $9.25 in cash per share they own. the investigation focuses on whether kindred biosciences, inc. and its board of directors violated securities laws and/or breached their fiduciary duties to the company by 1) failing to conduct a fair process, and 2) whether the transaction is properly valued.
2021-06-16 10:50:00 - Press Release
Kindred Biosciences Merger Investigation: Halper Sadeh Llp Announces Investigation Into Whether The Sale Of Kindred Biosciences, Inc. Is Fair To Shareholders; Investors Are Encouraged To Contact The Firm – Kin
New york--(business wire)--halper sadeh llp, a global investor rights law firm, is investigating whether the sale of kindred biosciences, inc. (nasdaq: kin) to elanco animal health incorporated for $9.25 per share is fair to kindred biosciences shareholders. halper sadeh encourages kindred biosciences shareholders to click here to learn more about their legal rights and options or contact daniel sadeh or zachary halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. the i
Latest News
2021-07-21 14:24:00 - PRNewsWire
SHAREHOLDER ALERT: WeissLaw LLP Reminds CVA, SWN, RIVE, and KIN Shareholders About Its Ongoing Investigations
NEW YORK, July 21, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. WeissLaw LLP1500 Broadway, 16th Floor New York, NY 10036 (212) 682-3025 (888) 593-4771 stockinfo@weisslawllp.com Covanta Holding Corporation (NYSE: CVA) WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Covanta Holding Corporation (NYSE: CVA) in connection with the proposed acquisition of the company by EQT Infrastructure.
2021-06-22 14:59:00 - PRNewsWire
Moore Kuehn Encourages KIN, SVOK, ROCR, and DCRC Investors to Contact Law Firm
NEW YORK, June 22, 2021 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies: Kindred Biosciences, Inc. (NASDAQ: KIN) Kindred Bioscience has agreed to merge with Elanco Health.
2021-06-16 19:30:00 - PRNewsWire
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Kindred Biosciences, Inc. - KIN
NEW YORK, June 16, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Kindred Biosciences, Inc. ("KIN" or the "Company") (KIN) relating to its proposed acquisition by Elanco Animal Health, Inc. KIN shareholders will receive $9.25 in cash per share they own. The investigation focuses on whether Kindred Biosciences, Inc. and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process, and 2) whether the transaction is properly valued.
2021-06-16 16:20:45 - The Motley Fool
Why Kindred Biosciences Stock Skyrocketed Today
2021-06-16 13:27:06 - Invezz
Kindred Biosciences to merge with Elanco Animal Health
Elanco Animal Health Inc (NYSE: ELAN) said on Wednesday it will acquire Kindred Biosciences Inc (NASDAQ: KIN) for roughly $440 million (£312 million) to expand its footprint in the pet health industry. The acquisition will bring three potential dermatology blockbusters, which are currently in the development phase, under Elanco's umbrella.
2021-06-16 12:30:10 - Benzinga
Why Kindred Biosciences, Aprea, Catabasis And Inhibikase Are Moving Today
Kindred Biosciences, Inc. (NASDAQ: KIN), Aprea Therapeutics, Inc. (NASDAQ: APRE), Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) and Inhibikase Therapeutics, Inc. (NASDAQ: IKT) are among the biggest biopharma movers on Wednesday. Kindred Flies On Buyout: Kindred announced an agreement to be bought by Elanco Animal Health Incorporated (NYSE: ELAN) for $9.25 per share, or approximately $440 million.
2021-06-16 10:50:00 - Business Wire
Kindred Biosciences Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Kindred Biosciences, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – KIN
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Kindred Biosciences, Inc. (NASDAQ: KIN) to Elanco Animal Health Incorporated for $9.25 per share is fair to Kindred Biosciences shareholders. Halper Sadeh encourages Kindred Biosciences shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The i
2021-06-16 07:12:24 - Pulse2
KIN Stock Price Increases Over 45% Pre-Market: Why It Happened
The stock price of Kindred Biosciences Inc (NASDAQ: KIN) increased by over 45% pre-market. This is why it happened.
2021-06-16 06:49:10 - Market Watch
Elanco Animal Health to acquire Kindred Biosciences for about $440 million; Kindred shares soar 45% premarket
Elanco Animal Health Inc. said Wednesday it has entered an agreement to acquire Kindred Biosciences Inc. for about $440 million, adding three potential dermatology blockbusters to its pipeline. Under the terms of the deal, Elanco will pay $9.l254 a share for each Kindred share owned, equal to a 52% premium based on the 30-day average closing price.
2021-06-03 09:47:28 - Zacks Investment Research
Kindred Bio (KIN) Soars 16%: Is Further Upside Left in the Stock?
Kindred Bio (KIN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.